Articles written by Vandana Singh - Benzinga

AstraZeneca's Andexxa steht der FDA-Überprüfung hinsichtlich Wirksamkeit und Sicherheitsbedenken gegenüber

Am Donnerstag wird das Beratungskomitee für Zell-, Gewebe- und Gentherapien eine Diskussion über den ergänzenden biologischen Antrag von AstraZeneca Plc (NASDAQ:AZN) für Andexxa (Rekombinanter inaktiver Faktor Xa (zhzo)

AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns

FDA panel to discuss AstraZeneca's supplemental application for Andexxa amid safety concerns, including thrombosis risks and efficacy limitations.

Novartis erhöht Verkaufsprognose für das mittlere Frist, CEO hebt robuste Pipeline hervor

Am Donnerstag erhöhte Novartis AG (NYSE:NVS) seine mittelfristige Umsatzprognose und hob sein Ziel für den jährlichen Wachstumskurs (CAGR) von 5 % auf 6 % für 2023-2028 an. Das Upgrade spiegelt die Leistung der

Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, and a promising innovation pipeline.

Fortschritte bei Krebsmedikamenten von Pyxis Oncology sorgen für Bedenken bei Analysten

Am Mittwoch veröffentlichte Pyxis Oncology, Inc. (NASDAQ:PYXS) vorläufige Daten aus der laufenden Dosis-Eskalationsstudie der Phase 1, in der PYX-201 bei mehreren soliden Tumoren evaluiert wird. Unter den auswertbaren

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer.

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

FDA gibt grünes Licht für Jazz Pharma's Krebsmedikament, ein Meilenstein für Zymework

Die US-amerikanische Gesundheitsbehörde FDA hat (JAZZ) Ziihera (Zanidatamab-Hrii) 50mg/ml zur intravenösen Injektion bei Erwachsenen mit zuvor behandeltem, nicht resezierbarem oder metastasiertem HER2-positivem (IHC 3+)

Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted

QuidelOrtho's secondary offering of 8.26 million shares is priced at $38.58, removing an investor overhang, according to William Blair's analysis.

Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate

Eli Lilly and Verge Genomics advance ALS drug development with validated targets and a Phase 1B study, part of their $694 million collaboration since 2021.

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System

PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing.

Inspire Medical's Strong 2025 Outlook And Upcoming Inspire V Launch Earns Analyst Upgrade

BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs

Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH resolution, and fibrosis improvement.

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints.

Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis

Quantum-Si partners with NVIDIA to advance AI-powered proteomics, collaborates with Avantor for U.S. and Canada distribution of protein sequencing tech.

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Aclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates.

Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst

Rocket Pharmaceuticals reveals RP-A501 Phase 1 data for Danon disease, showing durable efficacy, reduced cardiac biomarkers, and improved heart health.